Shipping estimate for one unit of the default specification to the United States: $45.00 USD . Final shipping depends on your cart and destination at checkout.
N-Acetyl Semax is explored for cognition and learning-related signaling; N-Acetyl Selank for anxiety and stress responses; Pinealon for reducing oxidative stress and protecting nerve cells; and PE-22-28 for TREK-1 inhibition and antidepressant-like activity. These research directions draw on parent-peptide, cell and animal studies and do not establish human benefits for the modified peptides or this blend. For laboratory research only.
N-Acetyl Semax, 20 mg: a modified Semax research peptide. Parent Semax has been studied in rats for hippocampal BDNF/TrkB signaling and learning-related responses. That study did not test this N-acetylated material or this blend; it is assay context, not proof of human cognitive benefit.
N-Acetyl Selank, 8 mg: a modified Selank research peptide associated with exploratory stress-response and neurobehavioral assays. A small clinical publication on parent Selank examined anxiety-related conditions, but did not test N-Acetyl Selank or this formulation. Parent-peptide findings cannot establish activity, potency or safety for this component.
Pinealon, 10 mg: the EDR tripeptide. Cell experiments reported reduced reactive-oxygen-species accumulation and necrotic cell death under experimentally induced oxidative stress. These observations support investigation of cellular stress responses; they do not demonstrate neuroprotection in humans.
PE-22-28, 10 mg: a shortened spadin analog studied for TREK-1 potassium-channel inhibition and antidepressant-like behavioral findings in mice. Mouse behavioral endpoints do not establish treatment efficacy in people.
Combination evidence: no clinical validation of this exact four-peptide blend was identified in the sources reviewed. Additive benefit, synergy, compatibility, stability and safety must not be inferred by adding together separate component studies.
Follow the lot-specific supplier instructions for transport, storage and laboratory handling. Keep the original container sealed, dry and protected from light; avoid excessive heat and repeated temperature changes. No blend-specific shelf life or solution stability is asserted without supporting batch data.
For analytical work, establish solvent compatibility, recovery, component identity and stability using a validated laboratory method. A single chromatographic purity value does not establish the quantity or identity of every component. Product imagery is illustrative and is not a batch analytical record.
This catalog entry represents the combined NASX20 + NASK8 + PIN10 + PE10 formulation, with each vial labeled as 20 mg + 8 mg + 10 mg + 10 mg. A kit contains 10 vials.
No. The total is 20 mg N-Acetyl Semax, 8 mg N-Acetyl Selank, 10 mg Pinealon and 10 mg PE-22-28 per vial.
No. They refer to N-acetylated derivatives. Confirm any additional terminal modifications from the batch documentation; parent-peptide research is not interchangeable evidence.
No clinical validation of this exact blend was identified in the reviewed sources. Component and parent-peptide studies do not prove benefits or safety for the mixture.
No. It is supplied for controlled laboratory research only. The labeled content is not a use dose or treatment recommendation.
Contact our online support for real-time communication about products, orders, shipping, payment, or bulk supply.
